vs
Side-by-side financial comparison of Arteris, Inc. (AIP) and Journey Medical Corp (DERM). Click either name above to swap in a different company.
Arteris, Inc. is the larger business by last-quarter revenue ($20.1M vs $16.1M, roughly 1.3× Journey Medical Corp). Journey Medical Corp runs the higher net margin — -7.8% vs -42.2%, a 34.5% gap on every dollar of revenue. On growth, Arteris, Inc. posted the faster year-over-year revenue change (30.0% vs 27.3%). Over the past eight quarters, Arteris, Inc.'s revenue compounded faster (24.7% CAGR vs 11.0%).
Arteris, Inc. is a multinational technology company headquartered in Campbell, California. It develops the network-on-chip (NoC) IP and system-on-chip (SoC) integration automation software that is used to create semiconductor chip and chiplet designs for a variety of devices, particularly in automotive electronics, artificial intelligence, machine learning, enterprise computing, communications, consumer, industrial, and aerospace & defense markets. The company specializes in the development a...
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
AIP vs DERM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.1M | $16.1M |
| Net Profit | $-8.5M | $-1.2M |
| Gross Margin | 90.8% | — |
| Operating Margin | -42.0% | -2.8% |
| Net Margin | -42.2% | -7.8% |
| Revenue YoY | 30.0% | 27.3% |
| Net Profit YoY | -3.7% | -182.0% |
| EPS (diluted) | $-0.19 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.1M | $16.1M | ||
| Q3 25 | $17.4M | $17.0M | ||
| Q2 25 | $16.5M | $15.0M | ||
| Q1 25 | $16.5M | $13.1M | ||
| Q4 24 | $15.5M | $12.6M | ||
| Q3 24 | $14.7M | $14.6M | ||
| Q2 24 | $14.6M | $14.9M | ||
| Q1 24 | $12.9M | $13.0M |
| Q4 25 | $-8.5M | $-1.2M | ||
| Q3 25 | $-9.0M | $-2.3M | ||
| Q2 25 | $-9.1M | $-3.8M | ||
| Q1 25 | $-8.1M | $-4.1M | ||
| Q4 24 | $-8.2M | $1.5M | ||
| Q3 24 | $-7.7M | $-2.4M | ||
| Q2 24 | $-8.3M | $-3.4M | ||
| Q1 24 | $-9.4M | $-10.4M |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 89.9% | — | ||
| Q2 25 | 89.4% | — | ||
| Q1 25 | 90.8% | — | ||
| Q4 24 | 89.8% | 82.3% | ||
| Q3 24 | 90.1% | 63.9% | ||
| Q2 24 | 90.0% | 56.0% | ||
| Q1 24 | 88.7% | 47.7% |
| Q4 25 | -42.0% | -2.8% | ||
| Q3 25 | -50.1% | -9.0% | ||
| Q2 25 | -50.0% | -19.2% | ||
| Q1 25 | -46.6% | -25.3% | ||
| Q4 24 | -45.9% | 17.7% | ||
| Q3 24 | -53.8% | -19.8% | ||
| Q2 24 | -51.1% | -19.7% | ||
| Q1 24 | -70.5% | -77.4% |
| Q4 25 | -42.2% | -7.8% | ||
| Q3 25 | -51.6% | -13.6% | ||
| Q2 25 | -55.3% | -25.3% | ||
| Q1 25 | -49.1% | -31.0% | ||
| Q4 24 | -53.0% | 12.1% | ||
| Q3 24 | -52.2% | -16.3% | ||
| Q2 24 | -57.2% | -22.6% | ||
| Q1 24 | -72.6% | -80.1% |
| Q4 25 | $-0.19 | $-0.04 | ||
| Q3 25 | $-0.21 | $-0.09 | ||
| Q2 25 | $-0.22 | $-0.16 | ||
| Q1 25 | $-0.20 | $-0.18 | ||
| Q4 24 | $-0.19 | $0.10 | ||
| Q3 24 | $-0.20 | $-0.12 | ||
| Q2 24 | $-0.22 | $-0.17 | ||
| Q1 24 | $-0.25 | $-0.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $33.9M | $24.1M |
| Total DebtLower is stronger | — | $25.3M |
| Stockholders' EquityBook value | $-14.6M | $31.9M |
| Total Assets | $115.0M | $94.6M |
| Debt / EquityLower = less leverage | — | 0.79× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $33.9M | $24.1M | ||
| Q3 25 | $39.0M | $24.9M | ||
| Q2 25 | $38.0M | $20.3M | ||
| Q1 25 | $42.3M | $21.1M | ||
| Q4 24 | $43.8M | $20.3M | ||
| Q3 24 | $48.7M | $22.5M | ||
| Q2 24 | $45.8M | $23.9M | ||
| Q1 24 | $44.8M | $24.1M |
| Q4 25 | — | $25.3M | ||
| Q3 25 | — | $25.2M | ||
| Q2 25 | — | $25.1M | ||
| Q1 25 | — | $25.0M | ||
| Q4 24 | — | $24.9M | ||
| Q3 24 | — | $19.8M | ||
| Q2 24 | — | $19.7M | ||
| Q1 24 | — | $14.7M |
| Q4 25 | $-14.6M | $31.9M | ||
| Q3 25 | $-11.4M | $25.9M | ||
| Q2 25 | $-7.5M | $19.2M | ||
| Q1 25 | $-4.8M | $21.5M | ||
| Q4 24 | $-1.2M | $20.1M | ||
| Q3 24 | $2.2M | $10.9M | ||
| Q2 24 | $5.3M | $11.3M | ||
| Q1 24 | $9.5M | $13.0M |
| Q4 25 | $115.0M | $94.6M | ||
| Q3 25 | $107.7M | $85.2M | ||
| Q2 25 | $106.9M | $81.2M | ||
| Q1 25 | $98.3M | $85.0M | ||
| Q4 24 | $106.1M | $80.2M | ||
| Q3 24 | $97.7M | $64.0M | ||
| Q2 24 | $96.4M | $65.2M | ||
| Q1 24 | $101.4M | $66.6M |
| Q4 25 | — | 0.79× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 1.30× | ||
| Q1 25 | — | 1.16× | ||
| Q4 24 | — | 1.24× | ||
| Q3 24 | — | 1.81× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | 1.13× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.2M | $-6.3M |
| Free Cash FlowOCF − Capex | $3.0M | — |
| FCF MarginFCF / Revenue | 15.1% | — |
| Capex IntensityCapex / Revenue | 0.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $5.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.2M | $-6.3M | ||
| Q3 25 | $3.2M | $-2.4M | ||
| Q2 25 | $-2.5M | $-942.0K | ||
| Q1 25 | $2.9M | $-2.8M | ||
| Q4 24 | $-2.6M | $2.2M | ||
| Q3 24 | $1.1M | $-1.2M | ||
| Q2 24 | $311.0K | $-5.2M | ||
| Q1 24 | $477.0K | $-5.0M |
| Q4 25 | $3.0M | — | ||
| Q3 25 | $2.5M | — | ||
| Q2 25 | $-2.8M | — | ||
| Q1 25 | $2.7M | — | ||
| Q4 24 | $-2.7M | — | ||
| Q3 24 | $1.1M | — | ||
| Q2 24 | $264.0K | — | ||
| Q1 24 | $281.0K | — |
| Q4 25 | 15.1% | — | ||
| Q3 25 | 14.2% | — | ||
| Q2 25 | -17.2% | — | ||
| Q1 25 | 16.2% | — | ||
| Q4 24 | -17.3% | — | ||
| Q3 24 | 7.4% | — | ||
| Q2 24 | 1.8% | — | ||
| Q1 24 | 2.2% | — |
| Q4 25 | 0.7% | — | ||
| Q3 25 | 4.1% | — | ||
| Q2 25 | 2.2% | — | ||
| Q1 25 | 1.1% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 0.2% | — | ||
| Q2 24 | 0.3% | — | ||
| Q1 24 | 1.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.46× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AIP
| License And Maintenance | $17.5M | 87% |
| Variable Royalties And Other | $2.6M | 13% |
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
